
Hepatitis D drug achieves 100% virologic response
Biopharmaceutical company Bluejay Therapeutics’ hepatitis drug candidate has achieved a 100% virologic response at week 48 of clinical trials. Brelovitug, an investigational, fully human, high-affinity monoclonal antibody (mAb), targets hepatitis B virus surface antigen (anti-HBsAg) in chronic hepatitis D (CHD). The company announced brelovitug achieved 100%… Read More

